These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8521379)

  • 1. Synergistic action of taxol and tiazofurin in human ovarian, pancreatic and lung carcinoma cells.
    Taniki T; Prajda N; Monden Y; Weber G
    Cancer Biochem Biophys; 1993 Sep; 13(4):295-302. PubMed ID: 8521379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms in the antiproliferative action of taxol and tiazofurin.
    Olah E; Csokay B; Prajda N; Kote-Jarai Z; Yeh YA; Weber G
    Anticancer Res; 1996; 16(5A):2469-77. PubMed ID: 8917337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic action of tiazofurin and genistein in human ovarian carcinoma cells.
    Li W; Weber G
    Oncol Res; 1998; 10(3):117-22. PubMed ID: 9700722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth inhibitory action of brefeldin A with taxol and tiazofurin in human breast carcinoma cells.
    Yeh YA; Weber G
    Cancer Biochem Biophys; 1995 Jun; 15(1):11-7. PubMed ID: 8536215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic action of taxol with tiazofurin and methotrexate in human breast cancer cells: schedule-dependence.
    Yeh YA; Olah E; Wendel JJ; Sledge GW; Weber G
    Life Sci; 1994; 54(24):PL431-5. PubMed ID: 7910932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antitumor effect of Tiazofurin (TR) consists of anti-proliferative and anti-invasive elements.
    Tóvári J; Bocsi J; Ladányi A; Lapis K; Timár J
    Anticancer Res; 1996; 16(6A):3307-12. PubMed ID: 9042305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells.
    Belotti D; Rieppi M; Nicoletti MI; Casazza AM; Fojo T; Taraboletti G; Giavazzi R
    Clin Cancer Res; 1996 Oct; 2(10):1725-30. PubMed ID: 9816123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased signal transduction activity and down-regulation in human cancer cells.
    Weber G; Shen F; Prajda N; Yeh YA; Yang H; Herenyiova M; Look KY
    Anticancer Res; 1996; 16(6A):3271-82. PubMed ID: 9042300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
    Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
    BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribavirin and quercetin synergistically downregulate signal transduction and are cytotoxic in human ovarian carcinoma cells.
    Li W; Shen F; Weber G
    Oncol Res; 1999; 11(5):243-7. PubMed ID: 10608619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic down-regulation of signal transduction and cytotoxicity by tiazofurin and quercetin in human ovarian carcinoma cells.
    Shen F; Herenyiova M; Weber G
    Life Sci; 1999; 64(21):1869-76. PubMed ID: 10353585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.
    Vadgama JV; Wu Y; Shen D; Hsia S; Block J
    Anticancer Res; 2000; 20(3A):1391-414. PubMed ID: 10928049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
    Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
    Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells.
    Jayaram HN; Zhen W; Gharehbaghi K
    Cancer Res; 1993 May; 53(10 Suppl):2344-8. PubMed ID: 8097964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
    Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line.
    Hata K; Osaki M; Dhar DK; Nakayama K; Fujiwaki R; Ito H; Nagasue N; Miyazaki K
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):68-74. PubMed ID: 14569416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tiazofurin: molecular and clinical action.
    Weber G; Prajda N; Abonyi M; Look KY; Tricot G
    Anticancer Res; 1996; 16(6A):3313-22. PubMed ID: 9042306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-hepatoma activity of taxol in vitro.
    Yuan JH; Wang XW; Luo D; Xie Y; Xie H
    Acta Pharmacol Sin; 2000 May; 21(5):450-4. PubMed ID: 11324445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids.
    Frankel A; Buckman R; Kerbel RS
    Cancer Res; 1997 Jun; 57(12):2388-93. PubMed ID: 9192815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of human ovarian carcinoma cell lines to antiprogestin mifepristone.
    Rose FV; Barnea ER
    Oncogene; 1996 Mar; 12(5):999-1003. PubMed ID: 8649817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.